Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Diastereoselective synthesis of new O-alkylated and C-branched inositols and their corresponding fluoro analogues.

Collet C, Chrétien F, Chapleur Y, Lamandé-Langle S.

Beilstein J Org Chem. 2016 Feb 25;12:353-61. doi: 10.3762/bjoc.12.39.

2.

The Luminescent Oligothiophene p-FTAA Converts Toxic Aβ1-42 Species into Nontoxic Amyloid Fibers with Altered Properties.

Civitelli L, Sandin L, Nelson E, Khattak SI, Brorsson AC, Kågedal K.

J Biol Chem. 2016 Apr 22;291(17):9233-43. doi: 10.1074/jbc.M115.696229.

3.

The "Other" Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry).

Thomas MP, Mills SJ, Potter BV.

Angew Chem Int Ed Engl. 2016 Jan 26;55(5):1614-50. doi: 10.1002/anie.201502227. Review.

4.
5.

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics.

Goure WF, Krafft GA, Jerecic J, Hefti F.

Alzheimers Res Ther. 2014 Jul 9;6(4):42. doi: 10.1186/alzrt272. Review.

6.

scyllo-Inositol promotes robust mutant Huntingtin protein degradation.

Lai AY, Lan CP, Hasan S, Brown ME, McLaurin J.

J Biol Chem. 2014 Feb 7;289(6):3666-76. doi: 10.1074/jbc.M113.501635.

7.

Synthesis and bioassay of β-(1,4)-D-mannans as potential agents against Alzheimer's disease.

Jiang RW, Du XG, Zhang X, Wang X, Hu DY, Meng T, Chen YL, Geng MY, Shen JK.

Acta Pharmacol Sin. 2013 Dec;34(12):1585-91. doi: 10.1038/aps.2013.104.

8.

Combination therapy in a transgenic model of Alzheimer's disease.

Aytan N, Choi JK, Carreras I, Kowall NW, Jenkins BG, Dedeoglu A.

Exp Neurol. 2013 Dec;250:228-38. doi: 10.1016/j.expneurol.2013.10.001.

9.

Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands.

Luo Y, Vali S, Sun S, Chen X, Liang X, Drozhzhina T, Popugaeva E, Bezprozvanny I.

ACS Chem Neurosci. 2013 Jun 19;4(6):952-62. doi: 10.1021/cn400011f.

10.

Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology.

Moon M, Song H, Hong HJ, Nam DW, Cha MY, Oh MS, Yu J, Ryu H, Mook-Jung I.

Cell Death Differ. 2013 Apr;20(4):630-8. doi: 10.1038/cdd.2012.161.

11.

Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers.

Attar A, Ripoli C, Riccardi E, Maiti P, Li Puma DD, Liu T, Hayes J, Jones MR, Lichti-Kaiser K, Yang F, Gale GD, Tseng CH, Tan M, Xie CW, Straudinger JL, Klärner FG, Schrader T, Frautschy SA, Grassi C, Bitan G.

Brain. 2012 Dec;135(Pt 12):3735-48. doi: 10.1093/brain/aws289.

12.

A peptide binding to the β-site of APP improves spatial memory and attenuates Aβ burden in Alzheimer's disease transgenic mice.

Yang SG, Wang SW, Zhao M, Zhang R, Zhou WW, Li YN, Su YJ, Zhang H, Yu XL, Liu RT.

PLoS One. 2012;7(11):e48540. doi: 10.1371/journal.pone.0048540.

13.

Treatment strategies targeting amyloid β-protein.

Schenk D, Basi GS, Pangalos MN.

Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006387. doi: 10.1101/cshperspect.a006387. Review.

14.

Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity.

Scopes DI, O'Hare E, Jeggo R, Whyment AD, Spanswick D, Kim EM, Gannon J, Amijee H, Treherne JM.

Br J Pharmacol. 2012 Sep;167(2):383-92. doi: 10.1111/j.1476-5381.2012.01973.x.

15.

Aβ(1-42) assembly in the presence of scyllo-inositol derivatives: identification of an oxime linkage as important for the development of assembly inhibitors.

Shaw JE, Chio J, Dasgupta S, Lai AY, Mo GC, Pang F, Thomason LA, Yang AJ, Yip CM, Nitz M, McLaurin J.

ACS Chem Neurosci. 2012 Mar 21;3(3):167-77. doi: 10.1021/cn2000926.

16.

Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.

Aileen Funke S, van Groen T, Kadish I, Bartnik D, Nagel-Steger L, Brener O, Sehl T, Batra-Safferling R, Moriscot C, Schoehn G, Horn AH, Müller-Schiffmann A, Korth C, Sticht H, Willbold D.

ACS Chem Neurosci. 2010 Sep 15;1(9):639-48. doi: 10.1021/cn100057j.

17.

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Danysz W, Parsons CG.

Br J Pharmacol. 2012 Sep;167(2):324-52. doi: 10.1111/j.1476-5381.2012.02057.x. Review.

18.

Natural amyloid-β oligomers acutely impair the formation of a contextual fear memory in mice.

Kittelberger KA, Piazza F, Tesco G, Reijmers LG.

PLoS One. 2012;7(1):e29940. doi: 10.1371/journal.pone.0029940.

19.

Peptides for therapy and diagnosis of Alzheimer's disease.

Funke SA, Willbold D.

Curr Pharm Des. 2012;18(6):755-67. Review.

20.

Cerebrovascular lesions induce transient β-amyloid deposition.

Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, Frosch MP, Greenberg SM, Bacskai BJ.

Brain. 2011 Dec;134(Pt 12):3697-707. doi: 10.1093/brain/awr300.

Supplemental Content

Support Center